Training Workshop: Training of BE Assessors Kiev, October 2009 Frequent Deficiencies Dr. Henrike Potthast Training workshop: Training.

Slides:



Advertisements
Similar presentations
Basic Principles of GMP
Advertisements

1 st Training Seminar on Planning and Preparing for EHES at the National Level Legal and ethical issues Susanna Conti Istituto Superiore di Sanità (ISS)
Tips to a Successful Monitoring Visit
WHO inspections of Contract Research Organizations.
© WHO – PSM Quality Control Laboratory Pharmaceutical Quality, Good manufacturing Practice & Bioequivalence Kiev, Ukraine October 2005 Maija Hietava.
Presentation of BE data in a product dossier Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Ensuring Better Services and Fair Value “Introduction and roadmap to implementation of ISO in Zambia’s water utilities” Kasenga Hara March 2015.
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
Audit Ebru Mutlu-Omega CRO. General Purpose to help quality (to maintain quality at present) to assure quality (make sure that quality in future is maintained)
World Health Organization
Good Clinical Practices Regulatory Guidelines for the Conduct of Clinical research Introduction to Research Pharmacy Services Javier Palacios, R.Ph. Sponsored.
1 MANUFACTURING AND PRODUCTION OF BIOLOGICAL PRODUCTS (ERT 455) HAZARD ANALYSIS AND CRITICAL CONTROL POINT (HACCP) SYSTEM Munira Mohamed Nazari School.
Quality control of raw materials In-process control
Slide 1 of 19D.K. Mubangizi, Dar Es Salaam Sept Training Workshop for Evaluators from National Medicines Regulatory Authorities in East African Community.
Reference, Retention and Reserve Samples
Session 6: Data Integrity and Inspection of e-Clinical Computerized Systems May 15, 2011 | Beijing, China Kim Nitahara Principal Consultant and CEO META.
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
Huzairy Hassan School of Bioprocess Engineering UniMAP.
Codex Guidelines for the Application of HACCP
Documentation –Part 2 Basic Principles of GMP Pharmaceutical Quality,
World Health Organization
Bioequivalence Studies Dr Sanet Aspinall, PhD Managing Director AddClin Research Pretoria 20 March 2009.
Federal Institute for Drugs and Medical Devices The BfArM is a Federal Institute within the portfolio of the Federal Ministry of Health 1 Quality of Bioequivalence.
Assessment of Interchangeable Multisource Medicines Quality of BE Data Dr. Henrike Potthast Training workshop: Assessment of Interchangeable.
Recapture of Day 1 Suchart Chongprasert, Ph.D. Food and Drug Administration “Practical Aspects in Performing Clinical and Bioanalytical Parts in BA/BE.
Workshop on Health Examination Surveys (HES) Legal and ethical issues Susanna Conti, M. Kanieff, G. Rago Istituto Superiore di Sanità (ISS) (National Public.
Project co-financed by European Union Project co- financed by Asean European Committee for Standardization Implementing Agency 1 Module 13 GMP Workshop.
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Analytical considerations
Railway Transport Equipment (RTE) Certification Railway Transport Equipment Certification Procedure Application for railway transport equipment certification.
WHO Workshop on Assessment of Bioequivalence Data Addis Ababa, 31. August – 3. September Frequent Deficiencies Dr. Henrike Potthast
Case studies Saila Antila, PhD WHO consultant Training workshop on Pharmaceutical Quality, Good Manufacturing Practice & Bioequivalence, Kiev
CLINICAL TRIALS – PHASE III. What are phase III trials  Confirmatory phase (Therapeutic confirmatory trial)  Trials are done to obtain sufficient evidence.
WHO Workshop on Assessment of Bioequivalence Data BCS-Biowaivers - Template Dr. Henrike Potthast WHO Workshop on Assessment of.
Read the SMALL PRINT of the 1572 The Essential GCP Document.
Important informations
WHO Prequalification Programme June 2007 Training Workshop on Dissolution, Pharmaceutical Product Interchangeability and Biopharmaceutical Classification.
Aloe Vera of America: A Quality IASC-Certified Producer of Aloe Vera Presented by Walt Jones.
Quality of Bioequivalence Data Alfredo García - Arieta Training workshop: Training of BE assessors, Kiev, October 2009.
Evaluation of quality and interchangeability of medicinal products - WHO Training workshop / 5-9 November |1 | Prequalification programme: Priority.
Assessment of Interchangeable Multisource Medicines BCS-Biowaivers - Template Dr. Henrike Potthast Training workshop: Assessment of.
30/02/2008 Dept. of Pharmaceutics 1 Salient Features of Quality Assurance Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor Department of Pharmaceutics.
 Definition of a quality Audit  Types of audit  Qualifications of quality auditors  The audit process.
Bundesinstitut für Arzneimittel und Medizinprodukte Pt WHO-consultant 1 WHO Training Workshop on Pharmaceutical Quality, Good Manufacturing Practice &
Diagnostic reference levels in Medical Imaging. Concept and practice
CBER Common Problems on Source Plasma Inspections Judy Ellen Ciaraldi BS, MT(ASCP)SBB, CQA(ASQ) CBER, OBRR, DBA September 16, 2009.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Examples of deficiencies in submitted data Drs. J. Welink Workshop on WHO prequalification requirements for reproductive health medicines, Jakarta, October.
Regulatory Issues in Laboratory Management
IP Accountability in Outpatient Clinical Trials
Module 12 - part 2Slide 1 of 23 WHO - EDM Basic Principles of GMP Documentation Part 2 Part One, 14.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Korea Food & Drug Administration Deputy director Kwang-Soo Joo Korea FDA Sep. 29, 2000 : Korean Good Clinical Practice & Relative Guidelines How to Manage.
Quality Control significance in pharmaceutical industry
Good Laboratory Practice
Evaluation of quality and interchangeability of medicinal products - EAC/EC/WHO Training workshop / September |1 | Prequalification programme:
Improving Compliance with ISAs Presenters: Al Johnson & Pat Hayle.
Office of the Medicaid Inspector General Home Health and Personal Care Audit Protocols James R. Kaiser
GCP (GOOD CLINICAL PRACTISE)
Responsibilities of Sponsor, Investigator and Monitor
Tanzania, August 2006 Dr. Barbara Sterzik, BfArM, Bonn 1 Bioequivalence dossier requirements for the prequalification project WHO Training Workshop.
BSB Biomanufacturing CHAPTER 4 GMP – Documentation Part I (SOP)
Responsibilities of Sponsor, Investigator and Monitor
LNH Pharma A Trusted Partner.
Documentation –Part 2 Basic Principles of GMP Pharmaceutical Quality,
Quality Assurance and Quality Control in Generics
Lesson 5: BRITE Seminar: GMP II
Elements of an Organized Regulatory Binder
Pharmacovigilance inspections: what HPRA expects
Panel discussion GMP inspection process – Health Canada
Presentation transcript:

Training Workshop: Training of BE Assessors Kiev, October 2009 Frequent Deficiencies Dr. Henrike Potthast Training workshop: Training of BE Assessors, Kiev, October 2009

Workshop: Training of BE Assessors, Kiev, October |2 | GCP/GLP Frequent Deficiencies Inspection of bioequivalence studies Critical and major deviations observed during WHO inspections of CROs by WHO inspectors GCP/GLP

Workshop: Training of BE Assessors, Kiev, October |3 | GCP/GLP Frequent Deficiencies Introduction Classification of deviations „Critical“ deviation means that this can lead to the conclusion that the study is not of a satisfactory level of compliance with the GCP/GLP. Several „major“ deviations can lead to the conclusion that the study is not of a satisfactory level of compliance with the GCP/GLP. „Minor“ deviations need to be addressed in order to sustained the confidence in the work of the organization. GCP/GLP

Workshop: Training of BE Assessors, Kiev, October |4 | GCP/GLP Frequent Deficiencies Critical deviations Clinical part eg.: No quality assurance system established (eg.: at the time of the study); Consent form not signed by subjects (eg.: case report form had been lost). GCP/GLP

Workshop: Training of BE Assessors, Kiev, October |5 | GCP/GLP Frequent Deficiencies The ethics committee is not operating and executing its tasks free from bias and from any influence of those who were conducting the trial. Neither the contract nor the protocol describes the responsibility for the design of the protocol Complex language is used in the informed consent forms to be signed by the subjects ("Stevens-Johnson Syndrome", "toxic epidermal necrolysis", "erythema multiforme" angiodema, neuropathy, anaphylaxis, steatosis ). GCP/GLP

Workshop: Training of BE Assessors, Kiev, October |6 | GCP/GLP Frequent Deficiencies No dosing procedure ( eg.: There was no quality assurance system established at the time when the study was done); No record of dosing or not sufficiently detailed (eg.: The dosing form was filled in advance, before dosing: box ticked for Treatment or Reference); No drug accountability form or inconsistencies (eg.: discrepancies between drug dispensed, dosed and returned). GCP/GLP

Workshop: Training of BE Assessors, Kiev, October |7 | GCP/GLP Frequent Deficiencies The identity of the medicinal product administered to each subject at each period of the trial can not be guaranteed due to insufficient documentation on the dispensing of the product Discrepancy between the protocol, the consent forms and the final report regarding the strength of the test product used GCP/GLP

Workshop: Training of BE Assessors, Kiev, October |8 | GCP/GLP Frequent Deficiencies The batch and the manufacturing date of the test product mentioned in the Certificate of Analysis were different of those indicated on the shipping letter. Lack of shipping letters for the reference products.

Workshop: Training of BE Assessors, Kiev, October |9 | GCP/GLP Frequent Deficiencies Reference product Case: manufacturer. Protocol : Study report:

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies No certificate of analysis or not sufficiently detailed (eg.: batch size for the test product was not mentioned or less than units) No record of dispensing or not sufficiently detailed (eg.: - only a typed form prepared in advance to help the staff for the dispensing; - no indication of date of preparation, of the operator, no signature of operator, no mention of double check, no record of line clearance…);

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies No drug testing was performed on the subjects. Therefore in fact there is no guarantee that the drug abstinence is respected. Subject withdrawal due to an adverse event (e.g. vomiting 4 hours post-dose) without any sufficient documentation. The decision was not taken by the investigator until more than 3 h after the event took place and 6 PK blood samples were unnecessarily taken.

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Identical ECGs for different Volunteers:

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies The composition of the meals versus protocol is not satisfactory as e.g. pizza toppings could be chosen by the volunteers. Consequently the meals are not standardized. Fasting and meals are not controlled during the study days. Records of the timing, duration of meals and amount of food and fluid consumed are missing.

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Storage condition of blood samples not monitored. (eg.: Temperature records were only kept for one freezer. Proper storage of the samples was therefore not documented. During the inspection the freezer for the blood sample storage did have a temperature drop to give alarm. The system had a red light signal but not the sound signal which should have been also the case according to the laboratory personnel).

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies The method of calculating AUC values (linear trapezoidal method or other, method of extrapolation to infinity) is not specified in the trial reports and/or incorrect.

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Case: t max. Blood sampling

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies The justification of the reintegration is not apparent (and not acceptable) and there is no source document to prove that the SOP for manual reintegration is followed (no signature, no date, no comment of authorized person on the chromatograms)

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Case: manipulation

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Case: remarkable data GCP/GLP

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies - LOQ: 10 ng/ml, sampling period 96 hours - AUC 0-t : 639 +/- 258 ng.h/ml - AUC inf : /- 379 ng.h/ml - C max : 31 +/- 14 ng/ml Analytical method Case: LOQ (1).

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Case: LOQ (2). Analytical method

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies The sample analysis of one subject is coded as “Outlier” (here: concentration much higher than other subjects for this time). The repeat analysis shows a different value but similar to those of other subject at this time. Therefore, the initial result cannot be left as “outlier”. An explanation must be provided (mixed samples?) and SOPs should cover such deviations.

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Several data found on chromatograms are not consistent with the final concentration reported by the bio-analytical laboratory but used for calculations Only one QC/batch at each concentration (LQC, MQC, HQC) is processed

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Bioanalytical part Critical deviations in %

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Bioanalytical part Major deviations in %

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies Use of correction-fluid and overwriting on CRFs and other raw data. Lack of documentation on monitoring and auditing …and more…

Workshop: Training of BE Assessors, Kiev, October | GCP/GLP Frequent Deficiencies THANK YOU FOR YOUR ATTENTION